Related Experiment Videos
Partial suppression of tumorigenicity in a human lung cancer cell line transfected with Krev-1
J Caamano1, M DiRado, T Iizasa
1Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennyslvania 19111.
Abstract:
A human non-small-cell lung carcinoma cell line, Calu-6 (from an anaplastic carcinoma), was transfected with the Ki-ras-related anti-oncogene Krev-1. Several transfectant lines were obtained that showed a reduced tumorigenicity in nude mice with respect to the parental and control transfected cell lines. This decrease was approximately 50% in tumor incidence at 4 wk after subcutaneous inoculation of the transfected cells. In addition, the volume of the Calu-6 revertant-derived tumors was three to 10 times smaller than that of the equivalent tumors produced by inoculation of the control cell line transfected with the neomycin-resistance gene. Krev-1--transfected cells that exhibited reduced tumorigenicity expressed Krev-1 mRNA and had variable numbers of copies of the Krev-1 gene. Moreover, Krev-1--transfected cells exhibited a more differentiated squamous epithelial morphology than the parental and control cell lines did. Moderately elevated levels of protein kinase C activity were detected in some revertant clones. Such activity correlated with the level of expression of Krev-1 mRNA in most cases. In summary, Krev-1 induced important morphological and biological changes in transfected Calu-6 cells that we interpreted as partial reversion of the malignant phenotype.
Insights
Introducing the Krev-1 anti-oncogene into lung cancer cells reduced tumor growth and promoted differentiation. This suggests Krev-1 may reverse malignant phenotypes in non-small-cell lung carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Non-small-cell lung carcinoma (NSCLC) is a major cause of cancer-related deaths.
- Understanding the molecular mechanisms underlying lung cancer progression is crucial for developing effective therapies.
- The Krev-1 anti-oncogene has been implicated in regulating cell growth and differentiation.
Purpose of the Study:
- To investigate the effect of Krev-1 transfection on the tumorigenicity and phenotype of human non-small-cell lung carcinoma (NSCLC) Calu-6 cells.
- To determine if Krev-1 expression can induce partial reversion of the malignant phenotype in lung cancer cells.
Main Methods:
- Transfection of Calu-6 NSCLC cells with the Krev-1 anti-oncogene.
- Assessment of tumor incidence and volume in nude mice after subcutaneous inoculation of transfected cells.
- Analysis of Krev-1 mRNA expression, gene copy number, and cellular morphology.
- Measurement of protein kinase C activity in revertant clones.
Main Results:
- Krev-1 transfection significantly reduced tumor incidence (approx. 50%) and tumor volume (3-10 fold smaller) in nude mice.
- Krev-1 transfected cells exhibited a more differentiated squamous epithelial morphology compared to controls.
- Elevated protein kinase C activity was observed in some Krev-1 expressing clones, correlating with Krev-1 mRNA levels.
Conclusions:
- Krev-1 expression induces significant morphological and biological changes in Calu-6 cells.
- These changes suggest a partial reversion of the malignant phenotype, indicating Krev-1's potential as a therapeutic target in NSCLC.